GlassScriptPhysician profile
Kory Matthew Simonsen
NPI 1417688136
$3,882.42
in general payments reported to CMS, 2019-2025
21 companies · $278 in 2025
The $278 reported for 2025 was more than what a typical Psychiatric/Mental Health (Nurse Practitioner) provider received nationally (typical 2025 total: $257).
See the full distribution for Psychiatric/Mental Health (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $464 · 2024: $3,140 · 2025: $278.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,687 · Travel and Lodging: $1,195.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,686.93 |
| Travel and Lodging | $1,195.49 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Neuronetics, INC. | $1,949.91 | 2024 | Neurostar Tms Therapy System |
| Otsuka America Pharmaceutical, INC. | $265.09 | 2023-2025 | Rexulti, Nuedexta |
| Idorsia Pharmaceuticals US INC | $189.52 | 2023-2024 | Quviviq |
| Neurocrine Biosciences, INC. | $186.61 | 2024 | Ingrezza |
| Axsome Therapeutics, INC. | $158.00 | 2024-2025 | Auvelity |
| Alkermes, INC. | $144.82 | 2025 | Lybalvi |
| Abbvie INC. | $134.23 | 2024-2025 | |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $124.83 | 2023 | Rexulti |
| E.R. Squibb & Sons, L.L.C. | $123.83 | 2024 | Cobenfy |
| Vanda Pharmaceuticals INC. | $112.05 | 2024 | Fanapt, Hetlioz |
| Bioxcel Therapeutics, INC. | $105.63 | 2023 | Igalmi |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $75.64 | 2023-2024 | Caplyta |
| Bausch Health US, LLC | $69.09 | 2023-2024 | Aplenzin |
| Lundbeck LLC | $68.58 | 2023-2025 | Rexulti |
| Tris Pharma INC | $41.05 | 2023-2024 | Dyanavel Xr |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $30.28 | 2024 | Spravato |
| Janssen Scientific Affairs, LLC | $24.67 | 2024 | Spravato |
| Takeda Pharmaceuticals U.S.A., INC. | $24.28 | 2024 | Trintellix |
| Tempus Ai, INC | $20.71 | 2024 | |
| Noven Therapeutics, LLC | $19.73 | 2024 | Secuado, Xelstrym |
| Merck Sharp & Dohme LLC | $13.87 | 2023 | Belsomra |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kory Simonsen listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.